CytomX Therapeutics (CTMX) Stock Forecast & Price Target $3.20 -0.08 (-2.44%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.21 +0.01 (+0.44%) As of 10/17/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CytomX Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating BuyBased on 7 Analyst RatingsSell0Hold1Buy6 Based on 7 Wall Street analysts who have issued ratings for CytomX Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for CTMX. Consensus Price Target $5.4269.27% Upside According to the 7 analysts' twelve-month price targets for CytomX Therapeutics, the average price target is $5.42. The highest price target for CTMX is $7.00, while the lowest price target for CTMX is $3.50. The average price target represents a forecasted upside of 69.27% from the current price of $3.20. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for CTMX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Analyst Ratings Over TimeTypeCurrent Forecast10/19/24 to 10/19/251 Month Ago9/19/24 to 9/19/253 Months Ago7/21/24 to 7/21/251 Year Ago10/20/23 to 10/19/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy5 Buy rating(s)4 Buy rating(s)3 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)0 Hold rating(s)0 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$5.42$5.30$5.33$5.77Forecasted Upside69.27% Upside167.68% Upside124.09% Upside389.19% UpsideConsensus RatingBuyBuyBuyModerate Buy CTMX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CTMX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table CytomX Therapeutics Stock vs. The CompetitionTypeCytomX TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 3.00 2.33 2.52Consensus RatingBuyHoldModerate BuyPredicted Upside69.27% Upside1,357.67% Upside13.60% UpsideNews Sentiment RatingNeutral NewsSee Recent CTMX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/8/2025Weiss Ratings0 of 5 stars UpgradeSell (D+) ➝ Hold (C-)9/22/2025Cantor Fitzgerald4 of 5 starsOlivia Brayer Not RatedInitiated CoverageOverweight$6.00+203.03%9/17/2025Barclays3 of 5 starsEtzer Darout Not RatedInitiated CoverageOverweight$3.50+78.57%7/31/2025OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew BieglerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$7.00+201.72%5/15/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph CatanzaroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$2.50 ➝ $5.00+151.26%5/15/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMitchell KapoorSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.00+110.08%5/12/2025WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform$5.00 ➝ $6.00+181.69%5/9/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetMarket Perform$3.25 ➝ $3.59+55.41%5/6/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Buy$2.50 ➝ $8.00+80.59%4/22/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeUnderweight ➝ Neutral Get the Latest News and Ratings for CTMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:30 PM ET. CTMX Forecast - Frequently Asked Questions What is CytomX Therapeutics' forecast for 2025? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for CytomX Therapeutics is $5.42, with a high forecast of $7.00 and a low forecast of $3.50. Should I buy or sell CytomX Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTMX shares. Does CytomX Therapeutics's stock price have much upside? According to analysts, CytomX Therapeutics's stock has a predicted upside of 69.27% based on their 12-month stock forecasts. Has CytomX Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, CytomX Therapeutics's stock had 2 upgrades by analysts. What analysts cover CytomX Therapeutics? CytomX Therapeutics has been rated by research analysts at Barclays, Cantor Fitzgerald, Oppenheimer, and Weiss Ratings in the past 90 days. Do Wall Street analysts like CytomX Therapeutics more than its competitors? Analysts like CytomX Therapeutics more than other "medical" companies. The consensus rating for CytomX Therapeutics is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CTMX compares to other companies. Stock Forecasts and Research Tools Related Companies 89BIO Stock Forecast Sarepta Therapeutics Stock Forecast Ocular Therapeutix Stock Forecast Dyne Therapeutics Stock Forecast ANI Pharmaceuticals Stock Forecast Vera Therapeutics Stock Forecast Tilray Brands Stock Forecast Twist Bioscience Stock Forecast Cogent Biosciences Stock Forecast Structure Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:CTMX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts